Page 4 - Norgine Annual Report 2017
P. 4


                                                    In 2017, Norgine continued its long track record of growth reaching            Norgine opened its new headquarters in the heart of Amsterdam’s business district, at Cross Towers, Antonio
                                                    €345 million net product sales, up 17 per cent. The revenue                    Vivaldistraat 150, 1083 HP Amsterdam, Netherlands – a key base to expand its European business, ensure attraction
                                                    increase was due to both the acquisition of Merus Labs International           and retention of talent from across Europe.
                                                    Inc. (“Merus”) and organic growth from Norgine’s key products.
                                                                                                                                   Norgine has a direct presence in 12 European countries, as well as Australia and New Zealand. Norgine employs
                                                            Products                                                               over 1,000 people, with around 380 in manufacturing and supply, 470 in commercial activities, and 160 in development,
                                                                                                                                   medical and regulatory, with the remainder employed in global shared services, general and administrative functions.
                                                    Norgine received the European approval for PLENVU and launched
                                                    it in the UK. PLENVU is the only 1-litre PEG bowel preparation for             Norgine does not over-rely on any single country and operates an adaptable infrastructure that allows commercialisation
                                                    cleansing of the colon prior to any procedure requiring a clean bowel.         of new products.

                                                                                                                                   Norgine is a fully integrated pharmaceutical business, with manufacturing sites in Hengoed, Wales and Dreux, France,
                                                            Growth strategy                                                        third party supply networks and significant product development capabilities, in addition to its sales and marketing

                                                    Norgine accelerated its growth strategy with the acquisition of Merus          infrastructure.
                                                    Labs International Inc. for C$342m. As a result of the transaction                                                                                               Over
                                                    Norgine acquired a product portfolio of 12 established products,                                                                                             OVER
                                                    including SINTROM , EMSELEX , ELANTAN , ISOKET , DEPONIT ,
                                                    SALAGEN  and ESTRADERM  which are sold across Europe and
                                                    other selected markets. Norgine leveraged its significant operating
                                                    infrastructure across Europe to more effectively support these products
                                                    while ensuring that the highest standards of quality are maintained.                                                                                        STAFF
                                                            Patients                                                                                                                                              Million
                                                    Norgine’s products were used by over 15 million patients.
                                                    Over the years, Norgine has established relationships with key
                                                    opinion leaders, professional organisations and health services to
                                                    help navigate complex systems and ensure that patients gain access
                                                    to its products. Norgine works together with healthcare professionals,
                                                    organisations and patient groups towards achieving common goals.
                                                    Our objective is to shape policies for the benefit of the patients or to             17
                                                    improve the understanding of complex diseases and treatments.
                                                                                                                                       GROWTH UP
       3                                                                                                                                                                                                                                4
   1   2   3   4   5   6   7   8   9